Recombinant Human bca-1 protein

BCA-1 (B-cell-attracting chemokine-1), also known as CXCL13. is a small secreted chemokine belonging to the CXC subfamily. It plays a critical role in directing B-cell migration and lymphoid tissue organization by binding to its receptor CXCR5. which is predominantly expressed on mature B-cells and follicular helper T-cells. Discovered in the late 1990s, BCA-1 is structurally characterized by a conserved chemokine fold stabilized by disulfide bonds, typical of the CXC family. Its gene is located on human chromosome 4 and is regulated during immune responses.

Recombinant BCA-1 protein is produced using biotechnological systems like *E. coli* or mammalian cells, enabling scalable and pure protein yields for research. This engineered form retains native bioactivity, allowing scientists to study its role in B-cell trafficking, lymphoid neogenesis, and pathological conditions such as autoimmune diseases (e.g., rheumatoid arthritis, lupus) and cancers (e.g., lymphoma). In vitro, recombinant BCA-1 is used to model immune cell migration assays, investigate signaling pathways, or screen therapeutic agents targeting the CXCL13-CXCR5 axis. Its relevance as a biomarker in chronic inflammation and cancer prognosis has also driven diagnostic applications. By providing a controlled and consistent source of functional protein, recombinant BCA-1 facilitates both basic research and drug development, bridging mechanistic studies to clinical translation.